Dr. Reddy's: More excitement in store - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr. Reddy's: More excitement in store

Aug 1, 2001

Dr. Reddy has recorded a 115% growth in net profit for 1QFY02, much in line with market expectations. The figures for the current quarter is on a consolidated basis with Cheminor drugs and American Remedies. To provide meaningful comparison, previous quarter numbers are also on a consolidated basis. International formulations sales and a breakthrough in generic business contributed to the surge in net profit. Sales growth was driven primarily by 89% growth in branded formulations exports. Domestic branded formulations grew by 21%, outsmarting the industry growth rates.

(Rs m)1QFY01*1QFY02*% change
Sales 2,146 283832.2%
Other Income718621.0%
Expenditure 1,737 218525.8%
Operating Profit (EBDIT) 409 654 59.6%
Operating Profit Margin (%)19.1%23.0%
Interest 11450-56.1%
Profit before Tax 281 577 105.3%
Profit after Tax/(Loss) 249 535 114.7%
Net profit margin (%)11.6%18.9%
No. of Shares (eoy) (m)38.238.2
Fully Diluted Earnings per share*26.156.0
P/E (at current price) 30.2
(**- annualised)
(*- Consolidated)

Operating margins registered a healthy increase of 390 basis points on the back of higher-margin formulation exports and a significant breakthrough in the US generics market. The margins in the US generics market are more than 50%. Savings in interest cost also contributed significantly to net profit growth. Dr. Reddy's utilised US$ 69 m from net ADR proceeds of US$ 124 m to repay its debt, which is in line with the ADR utilisation projections.

In a related development, the company cleared the final hurdle for launching 40 mg fluoxetine (generic of Eli Lilly's block buster product Prozac) in the US markets with a six month marketing exclusivity. Dr.Reddy's would be the first Indian company to receive such exclusivity which ensures very high margins for its products. The company expects to launch the product in first week of August.

At the current market of Rs 1,690, the stock trades at a P/e of 30x the annualised earnings for 1QFY02. . The company has also been quick in deploying its ADR funds, which removes concerns for a considerable drop in RoCE. The highlights of the first quarter results is the significant breakthrough in the US generics market. The windfall gains from fluoxetine exclusivity is expected to be the key earnings driver in the coming quarters (approximately the company is expected to earn US$ 16 m from marketing). Other valuation triggers for the stock at this point of time are probable acquisitions (the company has reserved US$ 78 m towards this), windfall gains from research pipeline and other breakthrough's in the generic market.. However, any negative news from R&D front or delay in lauching products for the generics market could lead to a fall in valuations as the markets have built lot of expectations from the company.

Dr. Reddy's has decided to go for stock split in the ratio of 2:1.

Equitymaster requests your view! Post a comment on "Dr. Reddy's: More excitement in store ". Click here!


More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 1, 2021 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks